DENVER — The
use of adjuvant chemotherapy in early - stage non-small cell lung cancer (NSCLC) patients improves overall survival (OS) and 5 - year OS in patients with tumor sizes ranging from 3.1 — 7 cm.
A Phase III Randomized
Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> or = 4 cm)- IIIA Non-Small Cell Lung Cancer (NSCLC)
We were thus able to conclude that age - related cognitive decline is accentuated by chemotherapy, providing basis for questioning the
place of adjuvant chemotherapy in this elderly patient population.
The only randomized
study of adjuvant chemotherapy in mucosal melanoma demonstrated significantly increased relapse - free and overall survival in patients receiving temozolomide and cisplatin, as compared with interferon alfa - 2b or observation.